Search clinical trials for: Second line

Total 22731 results

SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Celgene

Active, not recruiting

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

Multiple Myeloma

United States, Canada, Japan, Puerto Rico
Devalingam Mahalingam
Amgen

Withdrawn

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer | KRAS P.G12C

United States
AbbVie
Radiation Therapy Oncology Group

Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Glioblastoma | Gliosarcoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian Federation, Singapor... and more
UNC Lineberger Comprehensive Cancer Center
American Cancer Society, Inc.

Completed

Chemotherapy-related Cognitive Impairment and Acute Leukemia

Acute Myeloid Leukemia

United States
Pfizer

Active, not recruiting

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Breast Neoplasms

China, Taiwan, Hong Kong, Singapore, Thailand
Bayer

Terminated

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Uterine Fibroids

United States, Singapore, China, Malaysia, Israel, South Africa, Bulgaria, Czechia, New Zealand
Jiangsu Simcere Pharmaceutical Co., Ltd.
G1 Therapeutics, Inc.

Completed

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan

Extensive-stage Small-cell Lung Cancer

China
Consorzio Oncotech

Active, not recruiting

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

Metastatic Breast Cancer

Italy
Gradalis, Inc.

Terminated

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide (VITA)

Sarcoma | Neoplasms | Neoplasms, Connective and Soft Tissue | Neoplasms by Histologic Type | Sarcoma, Ewing | Neoplasms, Bone Tissue | Neoplasms, Connective Tissue | Ewing Sarcoma | Rare Diseases | Ewing's Tumor Metastatic | Ewing Family of Tumors | Ewing's Sarcoma Metastatic | Ewing's Tumor Recurrent

United States
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Kirby Institute
National Health and Medical Research Council, Australia; National Institute... and other collaborators

Active, not recruiting

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

HIV Infections

Mexico, Thailand, Malaysia, Argentina, Brazil, India, Nigeria, South Africa, Chile, Colombia, Guinea, Indonesia, Mali, Zimbabwe
Spanish Lung Cancer Group

Completed

Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)

Lung Cancer

Spain
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China, Korea, Republic of, Malaysia, Taiwan
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Esophageal Carcinoma | Esophagogastric Junction Carcinoma

China
National Cancer Institute, Naples
Mario Negri Institute for Pharmacological Research

Active, not recruiting

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (MITO16MANGO2b)

Recurrent Ovarian Cancer

France, Italy, Switzerland, Monaco, Greece
National Cancer Institute, Naples

Active, not recruiting

Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer (STREAM)

Advanced Colorectal Cancer

Italy
National Cancer Institute, Naples

Active, not recruiting

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Metastatic Castration-resistent Prostate Cancer

Italy
National Cancer Institute, Naples

Active, not recruiting

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (BEVERLY)

Non-squamous Non-small Cell Lung Cancer

Italy
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Completed

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Second Affiliated Hospital, School of Medicine,...

Withdrawn

Chronic Disease Health Management Information Platform

Hypertension

China
ViiV Healthcare
GlaxoSmithKline

Completed

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

HIV Infections

Argentina, Thailand, Russian Federation, Mexico, South Africa, Romania, China, Chile, Ukraine, Colombia, Peru, Brazil, Kenya
NovoCure GmbH

Active, not recruiting

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

United States, China, Israel, Spain, Austria, Canada, Hong Kong, Germany, France, Bulgaria, Croatia, Hungary, Italy, Poland, Serbia
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Gastric Adenocarcinoma

China
Bezmialem Vakif University

Completed

The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study

Dyspepsia | Gastrointestinal System Disease

Turkey
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Gastric Cancer

China
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus (LUCENCE)

Non-Small Cell Lung Cancer

Greece
Sir Run Run Shaw Hospital

Completed

A Multicentre Pilot Study of Midline Catheter's Tip at a Different Position in Antimicrobial Therapy

Infection

China
Yuhong Li

Completed

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Advanced Esophageal Carcinoma

China
Pfizer

Completed

Clostridium Difficile Vaccine Efficacy Trial (Clover)

Clostridium Difficile Infection

United States, Spain, Belgium, Taiwan, Japan, Portugal, Colombia, Korea, Republic of, Poland, Australia, Germany, Canada, Argentina, Bulgaria, Chile, Czechia, Finland, France, Hungary, Peru, Slovakia, Sweden, United Kingdom
Pfizer

Completed

Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment

Atrial Fibrillation

Czechia
Huazhong University of Science and Technology

Active, not recruiting

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Tianjin Medical University Cancer Institute and...

Completed

Chemotherapy Combined With Apatinib and PD-1 Antibody

Gastric Cancer

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Genentech, Inc.

Completed

A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

Brain Neoplasms | Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer

Breast Cancer

United States
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Hoffmann-La Roche

Completed

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

Belgium, Spain, France, Germany, United States, United Kingdom, Italy, Australia, Poland
Second Affiliated Hospital of Guangzhou Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaborators

Active, not recruiting

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Hepatocellular Carcinoma Non-resectable

China
University of Cape Town
Wellcome Trust; Médecins Sans Frontières, Belgium

Completed

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial (ARTIST)

HIV Infections

South Africa
M.D. Anderson Cancer Center
Genentech, Inc.; OSI Pharmaceuticals

Completed

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Liver Cancer

United States
Akeso
Akeso Pharmaceuticals, Inc.

Active, not recruiting

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Gastric Adenocarcinoma | Advanced Solid Tumors | Gastroesophageal Junction Adenocarcinoma

China
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
Amgen

Completed

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

Carcinoma | Cancer | Head and Neck Cancer | Metastatic Cancer | Oncology | Tumors | Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | Squamous Cell Carcinoma | Metastases
Gruppo Oncologico Italiano di Ricerca Clinica
Bioikos Ambiente Srl; Istituto Toscano Tumori; Temas srl; Mipharm S.p.A.; Bristol...

Active, not recruiting

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) (EDEN)

Squamous Non-small Cell Lung Cancer

Italy
TBF Genie Tissulaire

Terminated

Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft (ODPHOENIX2)

Cartilage Injury
AIO-Studien-gGmbH
AstraZeneca

Withdrawn

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

NSCLC Stage IV

Germany
Hutchison Medipharma Limited
Sun Yat-sen University

Active, not recruiting

A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (FRUTIGA)

Advanced Gastric Cancer

China
ETOP IBCSG Partners Foundation
Hoffmann-La Roche; AstraZeneca

Active, not recruiting

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) (BOOSTER)

Non Small Cell Lung Cancer Metastatic

Ireland, Singapore, Spain, Switzerland, Korea, Republic of, Netherlands
Merck KGaA, Darmstadt, Germany

Completed

c-Met Second-Line Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Germany

Search clinical trials for: Second line

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations